Nova Mentis Life Science Corp. (NMLSF)

USD 0.03

(0.0%)

Market Cap (In USD)

1.18 Million

Revenue (In USD)

25.4 Thousand

Net Income (In USD)

-1.22 Million

Avg. Volume

15.99 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0064-0.0825
PE
-
EPS
-
Beta Value
0.628
ISIN
CA66980V1067
CUSIP
66980V106
CIK
1689231
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. William Rascan
Employee Count
-
Website
https://www.novamentis.ca
Ipo Date
2008-06-27
Details
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.